Innova and TGR Enter Co-Marketing Agreement for Complementary Core Biotechnologies
By LabMedica International staff writers Posted on 02 Feb 2014 |
Combining ELISA technology from TGR BioSciences (Adelaide, Australia) with conjugation kits from Innova Biosciences (Cambridge, UK) improves ELISA sensitivity and reduces cost.
TGR develops rapid, high sensitivity ELISA systems using their CaptSure technology, and Innova provides superior bioconjugation systems. Having entered into the agreement to promote and co-market their highly complementary technologies, they can now provide customers with a major step forward in simplifying a laboratory's ELISA development process, while improving sensitivity and reducing costs.
TGR has determined that combining Innova’s "Lightning-Link" conjugation kits for the horseradish peroxidase (HRP) labeling of antibodies with its "CaptSure" technology enables rapid and cost-effective development of a wide range of high sensitivity ELISA assays. As part of the agreement, Innova customers will be introduced to the CaptSure technology as providing added value when used alongside Lightning-Link reagents. Similarly, Lightning-Link will be introduced to TGR customers with a recommendation of the added value when used alongside CaptSure products.
TGR’s CaptSure technology simplifies ELISA assays to one-step procedures, making them much faster and easier to carry out. Both assay antibodies are added to analyte at once, and after a single wash step, the HRP substrate is added to develop the signal. Importantly, manufacture and environmental costs are greatly reduced, since only a single assay plate is required (coated with CaptSure reagent) rather than a different plate for each target and the system requires much lower amounts of assay antibodies. Innova’s Lightning-Link conjugation system provides the ability to label antibodies with only 30 seconds hands-on time, while offering 100% yields and enhanced sensitivity over traditional labeling techniques and over other conjugation systems on the market.
“We’ve been impressed with Innova’s products. Their HRP conjugation kit is simple to use and at the same time provides performance that exceeds that of a range of other systems that we have tested. We are very happy to recommend Lightning-Link to anyone who is developing assays with our CaptSure system,” said Dr. Michael Crouch, Director of Business Development at TGR. Dr. Andy Lane, Executive Director at Innova Biosciences, said, "We are pleased to further develop our relationship with TGR. Their CaptSure technology provides advantages in ELISA assay development that are directly complementary to the ethos of our conjugation technology—simplicity, high speed, and enhanced sensitivity.”
Related Links:
TGR BioSciences
Innova Biosciences
TGR develops rapid, high sensitivity ELISA systems using their CaptSure technology, and Innova provides superior bioconjugation systems. Having entered into the agreement to promote and co-market their highly complementary technologies, they can now provide customers with a major step forward in simplifying a laboratory's ELISA development process, while improving sensitivity and reducing costs.
TGR has determined that combining Innova’s "Lightning-Link" conjugation kits for the horseradish peroxidase (HRP) labeling of antibodies with its "CaptSure" technology enables rapid and cost-effective development of a wide range of high sensitivity ELISA assays. As part of the agreement, Innova customers will be introduced to the CaptSure technology as providing added value when used alongside Lightning-Link reagents. Similarly, Lightning-Link will be introduced to TGR customers with a recommendation of the added value when used alongside CaptSure products.
TGR’s CaptSure technology simplifies ELISA assays to one-step procedures, making them much faster and easier to carry out. Both assay antibodies are added to analyte at once, and after a single wash step, the HRP substrate is added to develop the signal. Importantly, manufacture and environmental costs are greatly reduced, since only a single assay plate is required (coated with CaptSure reagent) rather than a different plate for each target and the system requires much lower amounts of assay antibodies. Innova’s Lightning-Link conjugation system provides the ability to label antibodies with only 30 seconds hands-on time, while offering 100% yields and enhanced sensitivity over traditional labeling techniques and over other conjugation systems on the market.
“We’ve been impressed with Innova’s products. Their HRP conjugation kit is simple to use and at the same time provides performance that exceeds that of a range of other systems that we have tested. We are very happy to recommend Lightning-Link to anyone who is developing assays with our CaptSure system,” said Dr. Michael Crouch, Director of Business Development at TGR. Dr. Andy Lane, Executive Director at Innova Biosciences, said, "We are pleased to further develop our relationship with TGR. Their CaptSure technology provides advantages in ELISA assay development that are directly complementary to the ethos of our conjugation technology—simplicity, high speed, and enhanced sensitivity.”
Related Links:
TGR BioSciences
Innova Biosciences
Latest Industry News
- Quanterix Completes Acquisition of Akoya Biosciences
- Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
- AMP Releases Best Practice Recommendations to Guide Clinical Laboratories Offering HRD Testing
- Illumina Acquires SomaLogic to Accelerate Proteomics Business
- Qiagen and Gencurix Partner on Development of QIAcuity Digital PCR IVD Assay
- QIAGEN and Incyte Enter into Precision Medicine Collaboration
- bioMérieux Acquires Day Zero Diagnostics Solutions and Technologies
- Aston University and BG Research Partner to Commercialize Groundbreaking Medical Diagnostic
- Fujirebio Collaborates with Stanford Medicine to Advance Infectious Disease Research
- QuidelOrtho to Acquire MDx Company LEX Diagnostics
- QIAGEN Enters into New Strategic Partnerships for Expanding MRD Testing Portfolio in Oncology
- Danaher and AstraZeneca Partner on Next Generation AI-Powered Diagnostics
- EuroMedLab 2025 Showcases Latest Technologies and Innovations in Laboratory Medicine
- Qiagen Acquires NGS Analysis Software Company Genoox
- Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
- Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Channels
Clinical Chemistry
view channel
New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
A new clinical chemistry analyzer is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories.... Read more
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read moreMolecular Diagnostics
view channel
Newly-Cleared Technology a Game Changer for Diagnosis of Lyme Disease
Lyme disease is one of the fastest-growing infectious diseases, with approximately 476,000 cases diagnosed annually in the United States. The symptoms of Lyme disease, such as fever, headache, fatigue,... Read more
Innovative Liquid Biopsy Test Uses RNA to Detect Early-Stage Cancer
Detecting and diagnosing cancer, particularly in its early stages, remains a significant challenge. Liquid biopsies offer a promising non-invasive alternative to traditional biopsies, which require removing... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment
Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Blood Test Detects Organ Rejection in Heart Transplant Patients
Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer
Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more
Computational Tool Exposes Hidden Cancer DNA Changes Influencing Treatment Resistance
Structural changes in tumor DNA are among the most damaging genetic alterations in cancer, yet they often go undetected, particularly when tissue samples are degraded or of low quality. These hidden genomic... Read moreMicrobiology
view channel
Viral Load Tests Can Help Predict Mpox Severity
Mpox is a viral infection that causes flu-like symptoms and a characteristic rash, which evolves significantly over time and varies between patients. The disease spreads mainly through direct contact with... Read more
Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic disorder marked by abnormal glucose metabolism during pregnancy, typically emerging in the mid to late stages. It significantly heightens the risk of... Read morePathology
view channel
AI Tool Enhances Interpretation of Tissue Samples by Pathologists
Malignant melanoma, a form of skin cancer, is diagnosed by pathologists based on tissue samples. A crucial aspect of this process is estimating the presence of tumor-infiltrating lymphocytes (TILs), immune... Read more
AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease
Senescent cells, which stop growing and reproducing due to injury, aging, or disease, play a critical role in wound repair and aging-related diseases like cancer and heart disease. These cells, however,... Read more
Novel Fluorescent Probe Shows Potential in Precision Cancer Diagnostics and Fluorescence-Guided Surgery
Hepatocellular carcinoma (HCC), a common type of liver cancer, is difficult to diagnose early and accurately due to the limitations of current diagnostic methods. Glycans, carbohydrate structures present... Read moreTechnology
view channel
Low-Cost Biosensing Technology Detects Disease Biomarkers in Minutes
Rapid at-home tests for diseases like COVID-19 have become increasingly popular for their convenience, but they come with a major drawback: they are less sensitive than the tests performed in medical settings.... Read more